NCT05456685 2025-10-28Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerAbbViePhase 2 Active not recruiting125 enrolled
NCT06390995 2025-06-15A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid TumorsTakedaPhase 1/2 Active not recruiting28 enrolled